Publications by authors named "Timothy Drevyanko"
Article Synopsis
- The study aimed to evaluate the effectiveness of induction chemotherapy before trimodality therapy in patients with esophageal or gastroesophageal junction adenocarcinoma, building on previous findings that suggested potential survival benefits.
- In a phase 2 trial involving 28 centers, patients were randomly assigned to receive either induction chemotherapy (Arm A) or none (Arm B) followed by standard treatment, with pathologic complete response (pathCR) as the primary measure of success.
- Results indicated that while the primary endpoint (pathCR) was not improved, patients receiving induction chemotherapy had significantly longer overall survival and disease-free survival, especially those with well/moderately differentiated tumors, prompting further investigation in future trials.
Purpose: This Phase II study was undertaken to define the efficacy and toxicity of the combination of docetaxel and irinotecan for the second-line treatment of non-small cell lung cancer (NSCLC).
Patients And Methods: Forty-six patients with measurable NSCLC who had relapsed after an initial response to chemotherapy or who had failed to respond to initial chemotherapy, received 130 mg/m2 of irinotecan IV over 90 minutes and 50 mg/m2 docetaxel IV over 60 minutes on Day 1 q3 weeks for 6 cycles. Dexamethasone and diphenhydramine pretreatment were given.